Gapping up
In reaction to strong earnings/guidance: CALM +7.2%
M&A news: QLIK +9% (exploring strategic alternatives amid pressure from activist investor Elliott Management, according to Reuters), LF +3.5% (Leapfrog receives, rejects unsolicited non-binding proposal from L&M Acquisitions for $1.10/share), YHOO +1.5% (Barrons suggesting that Yahoo (YHOO) could be sold)
Select metals/mining stocks trading higher: CLF +2.8%, VALE +2.2%, FCX+1.4%, X +0.5%
Other news: GBSN +35% (receives FDA 510(k) clearance for Staph ID/R Blood Culture Panel following submission in August 2015), ARLZ +15.9% (announces FDA acceptance of NDA for Yosprala for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers), ACAD +15.8% (FDA releases briefing documents ahead of March 29 AdComm for Nuplazid NDA), VMEM +15.2% (names Ebrahim Abbasi as Chief Operating Officer), LEU +14.3% (signs new U.S. Centrifuge Technology Advancement contract with UT-Battelle; totals ~$32.3 mln and runs through September 30), ALDR +7.4% (positive top-line data from two clinical trials evaluating ALD403 for migraine prevention that targets calcitonin gene-related peptide), VCEL +4.6% (publication of clinical trial rationale and study design for the phase 2b ixcell-DCM trial of ixmyelocel-t), DATA +1.7% (still checking), ZBH +1.3% (discloses that the DOJ and the SEC continue to evaluate alleged misconduct in Brazil and Mexico, as well as any issues relating to Biomet's compliance program)
Analyst comments: N/A
In reaction to strong earnings/guidance: CALM +7.2%
M&A news: QLIK +9% (exploring strategic alternatives amid pressure from activist investor Elliott Management, according to Reuters), LF +3.5% (Leapfrog receives, rejects unsolicited non-binding proposal from L&M Acquisitions for $1.10/share), YHOO +1.5% (Barrons suggesting that Yahoo (YHOO) could be sold)
Select metals/mining stocks trading higher: CLF +2.8%, VALE +2.2%, FCX+1.4%, X +0.5%
Other news: GBSN +35% (receives FDA 510(k) clearance for Staph ID/R Blood Culture Panel following submission in August 2015), ARLZ +15.9% (announces FDA acceptance of NDA for Yosprala for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers), ACAD +15.8% (FDA releases briefing documents ahead of March 29 AdComm for Nuplazid NDA), VMEM +15.2% (names Ebrahim Abbasi as Chief Operating Officer), LEU +14.3% (signs new U.S. Centrifuge Technology Advancement contract with UT-Battelle; totals ~$32.3 mln and runs through September 30), ALDR +7.4% (positive top-line data from two clinical trials evaluating ALD403 for migraine prevention that targets calcitonin gene-related peptide), VCEL +4.6% (publication of clinical trial rationale and study design for the phase 2b ixcell-DCM trial of ixmyelocel-t), DATA +1.7% (still checking), ZBH +1.3% (discloses that the DOJ and the SEC continue to evaluate alleged misconduct in Brazil and Mexico, as well as any issues relating to Biomet's compliance program)
Analyst comments: N/A